Vardenafil for the treatment of erectile dysfunction in men with diabetes / 中华男科学杂志
Xiaoxiong WANG.
National Journal of Andrology
; (12): 794-797, 2004.
Artículo
en Zh
| WPRIM | ID: wpr-267811
The prevalence of erectile dysfunction (ED) is higher in diabete patients than in non-diabete men. Moreover, the treatment of ED is more challenging in men with diabetes. Vardenafil, a novel and highly selective phosphodiesterase 5 inhibitor, is the first line therapy for the broad ED population. Recent large-scale clinical trials indicated that vardenafil improved erectile function in ED men with diabetes regardless of the baseline ED severity and plasma HbA1c levels, and it was generally well tolerated.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados